Skip to main content

Table 3 RFS and pCR rates for 42 patients classified by clinical and genetic characteristics

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

  Response to neoadjuvant chemotherapy Relapse-free survival
  pCR No pCR P-value No. of Patients (No. of events) 3-year estimates 95% CI P-value
All patients 20 17   42 (12) 0.72 0.55-0.89  
Response to neoadjuvant chemotherapy        
 pCR (grade 3)     20 (4) 0.73 0.52-0.93 0.764
 No pCR (grade 0~2)     17 (5) 0.86 0.67-1.04  
Hormone receptors        
 Positive 8 14 0.009 25 (7) 0.76 0.58-0.95 0.914
 Negative 12 3   17 (5) 0.69 0.42-0.95  
HER2 copy numbers        
 ≤ 2.0 1 6 0.019 8 (5) 0.57 0.20-0.94 0.095
 > 2.0 19 11   34 (7) 0.78 0.62-0.94  
Wild-type HER2 mRNA        
 < 400 8 9 0.208 20 (8) 0.61 0.40-0.83 0.022
 ≥ 400 11 5   17 (2) 0.92 0.76-1.07  
16HER2 mRNA        
 < 4.5 5 8 0.020 17 (5) 0.72 0.50-0.93 0.314
 ≥ 4.5 15 4   20 (5) 0.75 0.53-0.96  
Percentages of ∆16HER2 mRNA        
 < 2.4% 17 11 0.581 31 (6) 0.79 0.63-0.94 0.039
 ≥ 2.4% 5 1   6 (4) 0.50 0.10-0.90  
PIK3CA        
 Wild-type 18 14 0.498 36 (9) 0.79 0.64-0.94 0.171
 Mutated 2 3   6 (3) 0.42 −0.02-0.85  
PIK3CA        
 Wild-type + Normal + Loss + UPD 16 9 0.08 28 (6) 0.85 0.70-1.01 0.041
 Mutated + Gain 4 8   14 (6) 0.56 0.29-0.83  
PTEN        
 Normal + Gain + UPD 20 12 0.009 37 (11) 0.73 0.56-0.89 0.705
 Loss 0 5   5 (1) 0.80 0.45-1.15  
INPP4B        
 Normal + Gain + UPD 17 16 0.373 36 (8) 0.79 0.64-0.94 0.095
 Loss 3 1   6 (4) 0.50 0.10-0.90  
PI3KCA , PTEN, INPP4B        
 No aberrations* 14 6 0.086 22 (4) 0.81 0.60-1.01 0.195
 Aberrations** 6 11   20 (8) 0.67 0.45-0.89  
DEK        
 Normal 13 14 0.236 28 (5) 0.88 0.75-1.01 0.006
 Gain 7 3   14 (7) 0.44 0.14-0.75  
FGFR1        
 Normal + Loss + UPD 17 9 0.035 29 (9) 0.75 0.48-0.86 0.641
 Gain 3 8   13 (3) 0.92 0.76-1.07  
CCND1        
 Normal + Loss 11 12 0.33 25 (4) 0.84 0.68-1.01 0.043
 Gain 9 5   17 (8) 0.58 0.33-0.84  
FOXA1        
 Normal + UPD 15 13 0.917 30 (6) 0.80 0.64-0.96 0.012
 Gain 5 4   12 (6) 0.60 0.29-0.91  
CDH3        
 Normal + Loss + UPD 19 14 0.217 37 (8) 0.79 0.64-0.94 0.009
 Gain 1 3   5 (4) 0.40 −0.03-0.83  
BIRC5        
 Normal + Loss + UPD 14 13 0.659 27 (5) 0.82 0.66-0.98 0.005
 Gain 6 4   15 (7) 0.56 0.25-0.88  
MYBL2        
 Normal + Loss 18 10 0.028 30 (7) 0.80 0.64-0.96 0.053
 Gain 2 7   12 (5) 0.58 0.24-0.91  
AIB1        
 Normal + Loss 18 11 0.063 31 (7) 0.81 0.65-0.96 0.017
 Gain 2 6   11 (5) 0.52 0.15-0.89  
  1. CI, confidence interval; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.